The pursuit of therapeutic strategies to enhance muscle mass and combat degenerative muscle conditions has focused significant attention on the myostatin signaling pathway.

Mitochondrial-derived peptides (MDPs) represent a recently recognized class of bioactive microproteins encoded by short open-reading frames within the mitochondrial genome. Unlike nuclear-encoded peptides, MDPs originate from mitochondrial DNA and function as retrograde signaling molecules, communicating metabolic status from mitochondria to the nucleus. Among the identified MDPs, Humanin and MOTS-c have emerged as critical regulators of metabolic homeostasis, insulin sensitivity, and stress responses. For research facilities investigating metabolic disease, aging, and mitochondrial biology, understanding their distinct mechanisms of action and analytical considerations is essential.

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that has emerged as a significant target in adipocyte biology and metabolic regulation. Preclinical research demonstrates that 5-Amino-1MQ selectively inhibits NNMT with high potency and reduces lipid accumulation in adipocytes. In murine models of diet-induced obesity, the compound produces meaningful reductions in body weight, adipose tissue mass, and adipocyte size without altering food intake. However, critical gaps remain: no human safety, pharmacokinetic, or efficacy data exist for this compound, and it has not entered the FDA regulatory pathway.

LL-37 is the only human cathelicidin-derived antimicrobial peptide, a 37-amino-acid cationic molecule generated by cleavage of the hCAP18 protein. While its direct membrane-disrupting activity has been well characterised, recent research has revealed that LL-37 operates through multiple complementary mechanisms to defend against bacterial, viral, and fungal pathogens. The following analysis examines these mechanisms, with particular attention to applications relevant to infectious disease research.

The therapeutic rationale for dual GLP-1R/GCGR activation stems from the complementary metabolic effects of these two receptor pathways. While GLP-1R agonism enhances insulin sensitization and suppresses appetite, GCGR activation drives energy expenditure and hepatic fatty acid oxidation. This balanced approach enables superior weight reduction while circumventing the hyperglycemic risk inherent to isolated GCGR activation. Mazdutide achieves weight reductions of 11.3–14.84% over 24–48 weeks, demonstrating clinically meaningful efficacy across multiple metabolic parameters.